NCT00357747 - AEG35156 and Docetaxel in Treating Patients With Solid Tumors | Biotech Hunter

Enrollment

10

Participants

Timeline

Start Date

June 9, 2005

Primary Completion Date

September 26, 2006

Study Completion Date

June 7, 2010

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

AEG35156

After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.

DRUG

docetaxel

After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.

Trial Locations (3)

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

M5G 2M9

Univ. Health Network-Princess Margaret Hospital, Toronto

H2W 1S6

McGill University - Dept. Oncology, Montreal